Ovid Therapeutics Inc. $OVID

What the company doesAI summary of filing

Ovid Therapeutics is a biopharmaceutical company developing small molecule medicines for brain disorders, focusing on conditions characterized by neuronal hyperexcitation such as epilepsies and psychosis. The company is at the clinical-stage development phase with five ongoing clinical programs: OV329 (a GABA-aminotransferase inhibitor for drug-resistant seizures and developmental epileptic encephalopathies), OV4071 and other KCC2 direct activators (for psychosis associated with Parkinson's disease, Lewy body dementia, and schizophrenia), and preclinical programs for other psychiatric conditions. Ovid generates revenue through clinical and commercial milestones from in-licensed programs, including a $7.0 million payment received in 2025 from the sale of ganaxolone royalty rights to Immedica Pharma. The company has no marketed products and is pre-revenue from product sales, relying on milestone payments and equity financing. [10-K 2026-03-18]

Segments: OV329 (GABA-aminotransferase inhibitor), OV4071 (KCC2 direct activator), KCC2 direct activator portfolio, Ganaxolone royalty agreement (Immedica/Marinus)